GlaxoSmithKline's Push for an Ebola Vaccine

The video discusses GlaxoSmithKline's (GSK) efforts in developing an Ebola vaccine. In 2013, GSK acquired a company with an Ebola vaccine candidate. The World Health Organization (WHO) requested GSK to advance the vaccine to phase one trials amid the Ebola crisis. The trials are conducted in the US, UK, and West Africa, with results expected by the end of the year. The video highlights the lengthy vaccine development process and the collaboration between government, private industry, and charitable organizations to expedite trials. It also addresses the Ebola outbreak's impact and containment efforts in the US and West Africa.

How did GlaxoSmithKline become involved in the development of an Ebola vaccine?

• They developed the vaccine in-house.

• They received a government grant.

• They acquired a company with a vaccine candidate.

• They partnered with the World Health Organization.

What is the primary goal of the phase one trials for the Ebola vaccine?

• To produce the vaccine in large quantities.

• To determine the vaccine's safety.

• To test the vaccine's effectiveness.

• To distribute the vaccine globally.

Which organizations are collaborating to accelerate the Ebola vaccine development process?

• Only private companies.

• Only government agencies.

• Government, private industry, and charitable organizations.

• Only charitable organizations.

What is the expected outcome if the phase one trials are successful?

• Immediate global distribution of the vaccine.

• Initiation of phase two trials.

• Approval for emergency use without further trials.

• Discontinuation of the vaccine development.

What is a significant challenge in containing the Ebola outbreak in West Africa?

• Insufficient vaccine supply.

• Inadequate quarantine measures.

• Lack of international support.

• Limited media coverage.